Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Olumiant (baricitinib) tablets Right
  4. What is the recommended OLUMIANT® (baricitinib) dose for the treatment of rheumatoid arthritis?
Search Olumiant (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Baricitinib

Olumiant® (baricitinib) tablets

1mg, 2mg, 4mg
Full Prescribing Information

baricitinib

1mg, 2mg, 4mg

HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the recommended OLUMIANT® (baricitinib) dose for the treatment of rheumatoid arthritis?

The dosing regimen for Olumiant (baricitinib) in adult patients with moderately to severely active rheumatoid arthritis is 2 mg once daily.

US_cFAQ_BAR010A_DOSING_RA
US_cFAQ_BAR010A_DOSING_RA
en-US

Olumiant Prescribing Information

See important safety information, including boxed warning, in the attached prescribing information.

Dosing Considerations in Patients with Rheumatoid Arthritis

  • The recommended dose for baricitinib (BARI) in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers is 2 mg once daily with or without food.1
  • In patients with moderate renal impairment (estimated glomerular filtration rate (eGFR) between 30 and 60 mL/min/1.73 m2), the recommended dose of BARI is 1 mg once daily.1
  • In patients taking strong organic anion transporter 3 inhibitors, such as probenecid, the recommended dose of BARI is 1 mg once daily.1

Limitations of Use

Use of BARI is not recommended in patients with

  • severe renal impairment (eGFR <30 mL/min/1.73m2)
  • severe hepatic impairment
  • active, serious infection, including localized infections
  • absolute lymphocyte count <500 cells/mm3
  • absolute neutrophil count <1000 cells/mm3, or
  • hemoglobin level <8 g/dL.1

Dose Administration

Route of Administration

The appropriate dose of BARI is given orally once daily.1

Food Effects

Administration with meals is not associated with a clinically relevant effect on exposure.1

An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean area under the curve and maximum serum concentration of BARI by approximately 11% and 18%, respectively, and delayed the time to reach maximum serum concentration by 0.5 hours.1

In clinical studies, BARI was administered without regard to meals.1

Timing

Baricitinib can be taken at any time of day or night. It is best to take BARI at the same time every day.1,2

Use With Other Rheumatoid Arthritis Therapies

Baricitinib may be used as monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drug (DMARDs).1

Use of BARI is not recommended in combination with

  • other Janus kinase inhibitors
  • biologic DMARDs, or
  • potent immunosuppressants, such as azathioprine and cyclosporine.1

Use of Baricitinib With Vaccines

  • Avoid use of live vaccines with BARI.1
  • Update immunizations in agreement with current immunization guidelines prior to initiating BARI therapy.1

Enclosed Prescribing Information

OLUMIANT® (baricitinib) tablets, for oral use, Lilly

References

1Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: March 15, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly